| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Departments of Neurology (Dr. Fayad) and Neurosurgery (Dr. Awad), Yale University School of Medicine, New Haven, CT.
Address correspondence and reprint requests to Dr. Pierre B. Fayad, Yale University School of Medicine, Department of Neurology, 15 York Street, LCI-702, PO Box 208018, New Haven, CT 06520-8018.
Abstract.
Intracerebral hemorrhage (ICH) represents 8 to 15% of all strokes in the United States and 20 to 30% of all strokes in Japan and China. Although ICH represents a relatively small fraction of total strokes, it is a formidable disease, with a 30-day mortality rate two- to sixfold higher than that for ischemic stroke. Furthermore, it is a major cause of disability, with only 20% of patients becoming independent at 6 months. The most common risk factors for ICH are age, hypertension, and amyloid angiopathy, which are associated with damage to and weakening of the arterial/arteriolar wall leading to vessel rupture. The pathology is a dynamic one that continues to evolve over the first few days after onset. In 20 to 30% of ICH, clot volume increases over the first 24 hours and is generally associated with neurologic worsening. The final outcome from ICH is related not only to clot volume, compression, and destruction but also to potential neurotoxicity from the blood degradation products and associated neuronal ischemia. The treatment of ICH has been one of the most controversial and least well-studied areas from a medical or surgical perspective. Surgical treatment has evolved over the years and can be grouped into open and stereotactically guided surgery for hematoma evacuation. Seven thousand operations per year are performed in the United States for hematoma evacuation, although this approach has not been adequately investigated. Adjuvant medical therapies with neuroprotective agents require further investigation and may potentially have additive benefits.
This article has been cited by other articles:
|
|
 |
|
  J. R. Carhuapoma, P. B. Barker, D. F. Hanley, P. Wang, and N. J. Beauchamp Human Brain Hemorrhage: Quantification of Perihematoma Edema by Use of Diffusion-Weighted MR Imaging AJNR Am. J. Neuroradiol., September 1, 2002; 23(8): 1322 - 1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Rabinstein, J. L. Atkinson, and E. F.M. Wijdicks Emergency craniotomy in patients worsening due to expanded cerebral hematoma: To what purpose? Neurology, May 14, 2002; 58(9): 1367 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Kidwell, J. L. Saver, J. Mattiello, S. Warach, D. S. Liebeskind, S. Starkman, P. M. Vespa, J. P. Villablanca, N. A. Martin, J. Frazee, et al. Diffusion-perfusion MR evaluation of perihematomal injury in hyperacute intracerebral hemorrhage Neurology, November 13, 2001; 57(9): 1611 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Lapchak, D. F. Chapman, J. A. Zivin, and C. Y. Hsu Metalloproteinase Inhibition Reduces Thrombolytic (Tissue Plasminogen Activator)-Induced Hemorrhage After Thromboembolic Stroke Editorial Comment Stroke, December 1, 2000; 31(12): 3034 - 3040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Montes, J. H. Wong, P. B. Fayad, and I. A. Awad Stereotactic Computed Tomographic-Guided Aspiration and Thrombolysis of Intracerebral Hematoma : Protocol and Preliminary Experience Stroke, April 1, 2000; 31(4): 834 - 840. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
